Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  von Wyl, Viktor ^a   Klimkait, Thomas ^b   Yerly, Sabine ^c   Nicca, Dunja ^d   Furrer, Hansjakob ^e   Cavassini, Matthias ^f   Calmy, Alexandra ^c   Bernasconi, Enos ^g   Böni, Jürg ^h   Aubert, Vincent ^f   Günthard, Huldrych F ^a   Bucher, Heiner C ⁱ   Glass, Tracy R ^i,j  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; METHIONINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; VALINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CLASSIFICATION; ETHNIC GROUP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREDICTION; PROSPECTIVE STUDY; QUESTIONNAIRE; SWISS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION;

EID: 84885767147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077691     Document Type: Article

References (41)

1. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, et al. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353: 863-868. doi:10.1016/S0140-6736(99)01122-8. PubMed: 10093977.
2. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, et al. (2005) Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366: 378-384. doi:10.1016/S0140-6736(05)67022-5. PubMed: 16054937.
3. Glass TR, De Geest S, Hirschel B, Battegay M, Furrer H, et al. (2008) Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 13: 77-85. PubMed: 18389901.
4. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, et al. (2009) The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 50: 529-536. doi:10.1097/QAI.0b013e31819675e9. PubMed: 19223785.
5. Shuter J, (2008) Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 61: 769-773. doi:10.1093/jac/dkn020. PubMed: 18256112.
6. Bangsberg DR, (2006) Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43: 939-941. doi:10.1086/507526. PubMed: 16941380.
7. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146: 564-573. doi:10.7326/0003-4819-146-8-200704170-00007. PubMed: 17438315.
8. Liu H, Miller LG, Hays RD, Golin CE, Wu T, et al. (2006) Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 41: 315-322. doi:10.1097/01.qai.0000197071.77482.6e. PubMed: 16540932.
9. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, et al. (2012) Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26: 185-192. doi:10.1097/QAD.0b013e32834e9d7d. PubMed: 22179227. pii: 00002030-201201140-00008.
10. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, et al. (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17: 1925-1932. doi:10.1097/00002030-200309050-00011. PubMed: 12960825.
11. Burman W, Grund B, Neuhaus J, Douglas J Jr., Friedland G, et al. (2008) Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. J Acquir Immune Defic Syndr 49: 142-150. doi:10.1097/QAI.0b013e318183a9ad. PubMed: 18769356.
12. Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, et al. (2010) Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS 24: 395-403. doi:10.1097/QAD.0b013e328335cd8a. PubMed: 20099399.
13. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR, (2009) Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 23: 1035-1046. doi:10.1097/QAD.0b013e32832ba8ec. PubMed: 19381075.
14. Bangsberg DR, Moss AR, Deeks SG, (2004) Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 53: 696-699. doi:10.1093/jac/dkh162. PubMed: 15044425.
15. Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, et al. (2007) Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in N. HIV. Clin Trials 8: 282-292. doi:10.1310/hct0805-282.
16. Tam LW, Chui CK, Brumme CJ, Bangsberg DR, Montaner JS, et al. (2008) The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 49: 266-271. doi:10.1097/QAI.0b013e318189a753. PubMed: 18845950.
17. von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, et al. (2007) Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 167: 1782-1790. doi:10.1001/archinte.167.16.1782. PubMed: 17846398.
18. King MS, Brun SC, Kempf DJ, (2005) Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 191: 2046-2052. doi:10.1086/430387. PubMed: 15897990.
19. Harrigan PR, Wynhoven B, Brumme ZL, Brumme CJ, Sattha B, et al. (2005) HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 191: 1325-1330. doi:10.1086/428852. PubMed: 15776380.
20. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG, (2002) Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 30: 278-287. doi:10.1097/00042560-200207010-00003. PubMed: 12131564.
21. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, et al. (2004) Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis 190: 162-165. doi:10.1086/420790. PubMed: 15195256.
22. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, et al. (2006) Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20: 223-231. doi:10.1097/01.aids.0000199825.34241.49. PubMed: 16511415.
23. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311-1316. doi:10.1086/383572. PubMed: 15127346.
24. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE, (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37: 1112-1118. doi:10.1086/378301. PubMed: 14523777.
25. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, et al. (2009) Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients. Clin Infect Dis 48: 239-247. doi:10.1086/595703. PubMed: 19086910.
26. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335. doi:10.1001/jama.2011.375. PubMed: 21467286. doi:10.1001/jama.2011.375.
27. Metzner KJ, Rauch P, von WV, Leemann C, Grube C, et al. (2010) Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 201: 1063-1071. doi:10.1086/651136. PubMed: 20196655.
28. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, et al. (2000) Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 14: F111-F115. doi:10.1097/00002030-200007280-00001. PubMed: 10983633.
29. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, et al. (2008) Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 47: 421-424. doi:10.1086/589867. PubMed: 18558886.
30. Wainberg MA, Friedland G, (1998) Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279: 1977-1983. doi:10.1001/jama.279.24.1977. PubMed: 9643862.
31. Wittkop L, Günthard HF, de WF, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363-371. S1473- doi:10.1016/S1473-3099(11)70032-9. PubMed: 21354861. doi:10.1016/S1473-3099(11)70032-9.
32. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. (2010) Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 39: 1179-1189. doi:10.1093/ije/dyp321. PubMed: 19948780. doi:10.1093/ije/dyp321.
33. Kouyos RD, von W, [!(surname)!], Yerly S, Boni J, Taffe P, et al. (2010) Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 201: 1488-1497. doi:10.1086/651951. PubMed: 20384495.
34. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-164. PubMed: 22156218.
35. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260. doi:10.1056/NEJMoa051871. PubMed: 16421366. doi:10.1056/NEJMoa051871.
36. von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, et al. (2012) Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 54: 131-140. doi:10.1093/cid/cir728. PubMed: 22057700. doi:10.1093/cid/cir728.
37. Scherrer AU, Böni J, Yerly S, Klimkait T, Aubert V, et al. (2012) Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PLOS ONE 7: e50307. doi:10.1371/journal.pone.0050307. PubMed: 23189194. PONE-D-12-22916 [pii].
38. Gallego O, de MC, Pérez-Elías MJ, Guardiola JM, Pedreira J, et al. (2001) Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 15: 1701-1706. doi:10.1097/00002030-200109070-00014. PubMed: 11546946.
39. Miller RF, Shahmonesh M, Hanna MG, Unwin RJ, Schapira AH, et al. (2003) Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors. Antivir Ther 8: 253-257. PubMed: 12924544.
40. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, et al. (2008) Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 197: 1145-1155. doi:10.1086/529523. PubMed: 18476293.
41. Yerly S, von W, [!(surname)!], Ledergerber B, Boni J, Schupbach J, et al. (2007) Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21: 2223-2229. doi:10.1097/QAD.0b013e3282f0b685. PubMed: 18090050.